Bernard Coulie - Jan 23, 2025 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role: President and CEO, Director
Signature: /s/ Jennifer Woo, attorney-in-fact
Stock symbol: PLRX
Transactions as of: Jan 23, 2025
Transactions value $: $0
Form type: 4
Date filed: 1/27/2025, 05:58 PM
Previous filing: Jan 22, 2025
Next filing: Jun 20, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLRX	Common Stock	Award	$0	+163K	+37.75%	$0.00	593K	Jan 23, 2025	Direct	F1
holding	PLRX	Common Stock						409K	Jan 23, 2025	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PLRX	Stock Option (Right to Buy)	Award	$0	+325K		$0.00	325K	Jan 23, 2025	Common Stock	325K	$11.14	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
F2	Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3	1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.